4-Oxo-5-methyl-1,3,3a,7-tetraza-inden-carbonsaeure-(6)-aethylester;6-methyl-7-oxo-4,7-dihydro-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxylic acid ethyl ester;US10975084, Example 8-11;ethyl 6-methyl-7-oxo-1H-[1,2,4]triazolo[1,5-a]pyrimidine-5-carboxylate
CAS
90535-50-5
化学式
C9H10N4O3
mdl
——
分子量
222.203
InChiKey
OWHVPKMXBKYUFW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
物化性质
计算性质
ADMET
安全信息
SDS
制备方法与用途
上下游信息
反应信息
文献信息
表征谱图
同类化合物
相关功能分类
相关结构分类
计算性质
辛醇/水分配系数(LogP):
-0.1
重原子数:
16
可旋转键数:
3
环数:
2.0
sp3杂化的碳原子比例:
0.33
拓扑面积:
83.4
氢给体数:
1
氢受体数:
4
文献信息
[EN] KDM5 INHIBITORS<br/>[FR] INHIBITEURS DE KDM5
申请人:MERCK SHARP & DOHME
公开号:WO2018071283A1
公开(公告)日:2018-04-19
The present invention provides a compound of Formula (I) (represented as tautomers Ia and Ib) or the pharmaceutically acceptable salts thereof, which are KDM5 inhibitors.
The present invention provides a compound of Formula (I) (represented as tautomers Ia and Ib) or the pharmaceutically acceptable salts thereof, which are KDM5 inhibitors.
本发明提供了一种式(I)化合物(以同系物 Ia 和 Ib 表示)或其药学上可接受的盐,它们是 KDM5 抑制剂。
KDM5 INHIBITORS
申请人:MANSOOR UMAR Faruk
公开号:US20200048258A1
公开(公告)日:2020-02-13
The present invention provides a compound of Formula (I) (represented as tautomers Ia and Ib) or the pharmaceutically acceptable salts thereof, which are KDM5 inhibitors.